64127-44-2

Basic information

• Product Name: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER
• Synonyms: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER;ETHYL 4-CYCLOHEXYL-3-OXOBUTANOATE;4-Cyclohexyl-3-oxobutanoic acid ethyl ester
• CAS NO: 64127-44-2
• Molecular Formula: C₁₂H₂₀O₃
• Molecular Weight: 212.29
• Mol File: 64127-44-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 292.336 °C at 760 mmHg
• Flash Point: 123.844 °C
• Appearance: /
• Density: 1.008 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.457
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(64127-44-2)
• EPA Substance Registry System: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(64127-44-2)

Safety Data

• Hazardous Substances Data: 64127-44-2(Hazardous Substances Data)

Usage

General Description

4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER is a chemical compound with the molecular formula C12H20O3. It is an ester derivative of 4-cyclohexyl-3-oxobutyric acid, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical compounds. It is a clear, colorless liquid with a fruity odor, and is soluble in organic solvents such as ethanol and acetone. This chemical is known for its potential applications in the production of anti-inflammatory, analgesic, and anti-cancer drugs, making it an important intermediate in the synthesis of pharmaceutical compounds.

InChI:InChI=1/C12H20O3/c1-2-15-12(14)9-11(13)8-10-6-4-3-5-7-10/h10H,2-9H2,1H3

Upstream product

• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 23860-35-7 cyclohexylacetic acid chloride 
• 2033-24-1 cycl-isopropylidene malonate 
• 64-17-5 ethanol 
• 5292-21-7 Cyclohexylacetic acid 
• 6148-64-7 ethyl potassium malonate 
• 141-78-6 ethyl acetate 
• 1071-46-1 hydrogen ethyl malonate 
• 103-78-6 4-cyclohexyl-butan-2-one 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 74632-02-3 5-Cyclohexyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 158779-34-1 3-N-allyl-6-cyclohexylmethyl-2-thiouracil 
• 1561959-88-3 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-N-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-carboxamide 
• 349496-81-7 ethyl 5-(cyclohexylmethyl)-1H-pyrazole-3-carboxylate 
• 1561965-60-3 ethyl 5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylate 
• 1561965-63-6 ethyl 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylate 
• 1561965-64-7 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylic acid 
• 1561965-67-0 ethyl 5-(cyclohexylmethyl)-4-fluoro-1H-pyrazole-3-carboxylate 

Relevant articles and documents

Fungal Dioxygenase AsqJ Is Promiscuous and Bimodal: Substrate-Directed Formation of Quinolones versus Quinazolinones

Previous studies showed that the FeII/α-ketoglutarate dependent dioxygenase AsqJ induces a skeletal rearrangement in viridicatin biosynthesis in Aspergillus nidulans, generating a quinolone scaffold from benzo[1,4]diazepine-2,5-dione substrates. We report that AsqJ catalyzes an additional, entirely different reaction, simply by a change in substituent in the benzodiazepinedione substrate. This new mechanism is established by substrate screening, application of functional probes, and computational analysis. AsqJ excises H2CO from the heterocyclic ring structure of suitable benzo[1,4]diazepine-2,5-dione substrates to generate quinazolinones. This novel AsqJ catalysis pathway is governed by a single substituent within the complex substrate. This unique substrate-directed reactivity of AsqJ enables the targeted biocatalytic generation of either quinolones or quinazolinones, two alkaloid frameworks of exceptional biomedical relevance.

Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABAA receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents (e.g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an α- and a γ-subunit in the GABAA receptor, selected compounds were tested on the α1β2γ2s, α2β2γ2s and α3β2γ2s GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for α1- versus α2- and α3-containing receptors, and high-affinity ligands essentially selective for α1 over α3 were developed.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.